PTPRC and gastric cancer: A comparison of GC patients based on high (≥9.2% median level) versus low (<9.2%) CD45+CD33lowCD11bdim myeloid cell frequencies showed that the 35-month survival rate was significantly lower in patients with a higher CD45+CD33lowCD11bdim myeloid cell frequency (Fig. 6a).